BACKGROUND AND AIMS: Colorectal cancer (CRC) is the second most frequent cancer in developed countries. Newfoundland has the highest incidence of CRC in Canada and the highest rate of familial CRC yet reported in the world. To determine the impact of mutations in known CRC susceptibility genes and the contribution of the known pathways to the development of hereditary CRC, an incident cohort of 750 patients with CRC (708 different families) from the Newfoundland population was studied. METHODS: Microsatellite instability (MSI) testing was performed on tumours, together with immunohistochemistry analysis for mismatch repair (MMR) genes. Where indicated, DNA sequencing and multiplex ligation-dependent probe amplifications of MMR genes and APC was undertaken. DNA from all patients was screened for MUTYH mutations. The presence of the BRAF variant, p.V600E, and of MLH1 promoter methylation was also tested in tumours. RESULTS: 4.6% of patients fulfilled the Amsterdam criteria (AC), and an additional 44.6% fulfilled the revised Bethesda criteria. MSI-high (MSI-H) was observed in 10.7% (n=78) of 732 tumours. In 3.6% (n=27) of patients, CRC was attributed to 12 different inherited mutations in six known CRC-related genes associated with chromosomal instability or MSI pathways. Seven patients (0.9%) carried a mutation in APC or biallelic mutations in MUTYH. Of 20 patients (2.7%) with mutations in MMR genes, 14 (70%) had one of two MSH2 founder mutations. 17 of 28 (61%) AC families did not have a genetic cause identified, of which 15 kindreds fulfilled the criteria for familial CRC type X (FCCTX). CONCLUSIONS: Founder mutations accounted for only 2.1% of cases and this was insufficient to explain the high rate of familial CRC. Many of the families classified as FCCTX may have highly penetrant mutations segregating in a Mendelian-like manner. These families will be important for identifying additional CRC susceptibility loci.
BACKGROUND AND AIMS: Colorectal cancer (CRC) is the second most frequent cancer in developed countries. Newfoundland has the highest incidence of CRC in Canada and the highest rate of familial CRC yet reported in the world. To determine the impact of mutations in known CRC susceptibility genes and the contribution of the known pathways to the development of hereditary CRC, an incident cohort of 750 patients with CRC (708 different families) from the Newfoundland population was studied. METHODS:Microsatellite instability (MSI) testing was performed on tumours, together with immunohistochemistry analysis for mismatch repair (MMR) genes. Where indicated, DNA sequencing and multiplex ligation-dependent probe amplifications of MMR genes and APC was undertaken. DNA from all patients was screened for MUTYH mutations. The presence of the BRAF variant, p.V600E, and of MLH1 promoter methylation was also tested in tumours. RESULTS: 4.6% of patients fulfilled the Amsterdam criteria (AC), and an additional 44.6% fulfilled the revised Bethesda criteria. MSI-high (MSI-H) was observed in 10.7% (n=78) of 732 tumours. In 3.6% (n=27) of patients, CRC was attributed to 12 different inherited mutations in six known CRC-related genes associated with chromosomal instability or MSI pathways. Seven patients (0.9%) carried a mutation in APC or biallelic mutations in MUTYH. Of 20 patients (2.7%) with mutations in MMR genes, 14 (70%) had one of two MSH2 founder mutations. 17 of 28 (61%) AC families did not have a genetic cause identified, of which 15 kindreds fulfilled the criteria for familial CRC type X (FCCTX). CONCLUSIONS: Founder mutations accounted for only 2.1% of cases and this was insufficient to explain the high rate of familial CRC. Many of the families classified as FCCTX may have highly penetrant mutations segregating in a Mendelian-like manner. These families will be important for identifying additional CRC susceptibility loci.
Authors: L Spirio; J Green; J Robertson; M Robertson; B Otterud; J Sheldon; E Howse; R Green; J Groden; R White; M Leppert Journal: Hum Genet Date: 1999-11 Impact factor: 4.132
Authors: Joanne Young; Melissa A Barker; Lisa A Simms; Michael D Walsh; Kelli G Biden; Daniel Buchanan; Ron Buttenshaw; Vicki L J Whitehall; Sven Arnold; Leigh Jackson; Takeshi Kambara; Kevin J Spring; Mark A Jenkins; Graeme J Walker; John L Hopper; Barbara A Leggett; Jeremy R Jass Journal: Clin Gastroenterol Hepatol Date: 2005-03 Impact factor: 11.382
Authors: Marina E Croitoru; Sean P Cleary; Nando Di Nicola; Michael Manno; Teresa Selander; Melyssa Aronson; Mark Redston; Michelle Cotterchio; Julia Knight; Robert Gryfe; Steven Gallinger Journal: J Natl Cancer Inst Date: 2004-11-03 Impact factor: 13.506
Authors: Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11-02 Impact factor: 4.254
Authors: Deborah W Neklason; Richard A Kerber; David B Nilson; Hoda Anton-Culver; Ann G Schwartz; Constance A Griffin; Jan T Lowery; Joellen M Schildkraut; James P Evans; Gail E Tomlinson; Louise C Strong; Alexander R Miller; Jill E Stopfer; Dianne M Finkelstein; Prakash M Nadkarni; Carol H Kasten; Geraldine P Mineau; Randall W Burt Journal: Cancer Res Date: 2008-11-01 Impact factor: 12.701
Authors: Susan M Farrington; Albert Tenesa; Rebecca Barnetson; Alice Wiltshire; James Prendergast; Mary Porteous; Harry Campbell; Malcolm G Dunlop Journal: Am J Hum Genet Date: 2005-05-03 Impact factor: 11.025
Authors: M Pedroni; B Roncari; S Maffei; L Losi; A Scarselli; C Di Gregorio; M Marino; L Roncucci; P Benatti; G Ponti; G Rossi; M Menigatti; A Viel; M Genuardi; M Ponz de Leon Journal: Dis Markers Date: 2007 Impact factor: 3.434
Authors: Aung Ko Win; Mark A Jenkins; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Graham G Giles; Jack Goldblatt; Barbara A Leggett; John L Hopper; Stephen N Thibodeau; Noralane M Lindor Journal: J Med Genet Date: 2011-06-02 Impact factor: 6.318
Authors: Daniel G Luba; James A DiSario; Colleen Rock; Devki Saraiya; Kelsey Moyes; Krystal Brown; Kristen Rushton; Maydeen M Ogara; Mona Raphael; Dayna Zimmerman; Kimmie Garrido; Evelyn Silguero; Jonathan Nelson; Matthew B Yurgelun; Fay Kastrinos; Richard J Wenstrup; Sapna Syngal Journal: Clin Gastroenterol Hepatol Date: 2017-06-28 Impact factor: 11.382
Authors: María Laura González; Natalia Causada-Calo; Juan Pablo Santino; Mev Dominguez-Valentin; Fabiana Alejandra Ferro; Inés Sammartino; Pablo Germán Kalfayan; Maria Alicia Verzura; Tamara Alejandra Piñero; Andrea Romina Cajal; Walter Pavicic; Carlos Vaccaro Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375
Authors: Matthew B Yurgelun; Matthew H Kulke; Charles S Fuchs; Brian A Allen; Hajime Uno; Jason L Hornick; Chinedu I Ukaegbu; Lauren K Brais; Philip G McNamara; Robert J Mayer; Deborah Schrag; Jeffrey A Meyerhardt; Kimmie Ng; John Kidd; Nanda Singh; Anne-Renee Hartman; Richard J Wenstrup; Sapna Syngal Journal: J Clin Oncol Date: 2017-01-30 Impact factor: 44.544
Authors: H Rothenmund; H Singh; B Candas; B N Chodirker; K Serfas; M Aronson; S Holter; A Volenik; J Green; E Dicks; M O Woods; D Gilchrist; R Gryfe; Z Cohen; W D Foulkes Journal: Curr Oncol Date: 2013-10 Impact factor: 3.677